JP7843248B2 - ＡＰＲＩＬ結合抗体によるＩｇＡ腎症を治療する方法 - Google Patents

ＡＰＲＩＬ結合抗体によるＩｇＡ腎症を治療する方法

Info

Publication number
JP7843248B2
JP7843248B2 JP2022573609A JP2022573609A JP7843248B2 JP 7843248 B2 JP7843248 B2 JP 7843248B2 JP 2022573609 A JP2022573609 A JP 2022573609A JP 2022573609 A JP2022573609 A JP 2022573609A JP 7843248 B2 JP7843248 B2 JP 7843248B2
Authority
JP
Japan
Prior art keywords
antibody
approximately
april
administration
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022573609A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527563A (ja
JP2023527563A5 (enExample
Inventor
デ ラール，トゥウン ヴァン
ホナーマンド，ソマイエ
ドゥロス，ジョン
コック，エデュアルド デ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aduro Biotech Holdings Europe BV
Original Assignee
Aduro Biotech Holdings Europe BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aduro Biotech Holdings Europe BV filed Critical Aduro Biotech Holdings Europe BV
Publication of JP2023527563A publication Critical patent/JP2023527563A/ja
Publication of JP2023527563A5 publication Critical patent/JP2023527563A5/ja
Priority to JP2026056121A priority Critical patent/JP2026126199A/ja
Application granted granted Critical
Publication of JP7843248B2 publication Critical patent/JP7843248B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2022573609A 2020-05-29 2021-05-28 ＡＰＲＩＬ結合抗体によるＩｇＡ腎症を治療する方法 Active JP7843248B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026056121A JP2026126199A (ja) 2020-05-29 2026-03-30 ＡＰＲＩＬ結合抗体によるＩｇＡ腎症を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062704831P 2020-05-29 2020-05-29
US62/704,831 2020-05-29
PCT/US2021/035011 WO2021243298A1 (en) 2020-05-29 2021-05-28 Methods of treating iga nephropathy with an april binding antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026056121A Division JP2026126199A (ja) 2020-05-29 2026-03-30 ＡＰＲＩＬ結合抗体によるＩｇＡ腎症を治療する方法

Publications (3)

Publication Number Publication Date
JP2023527563A JP2023527563A (ja) 2023-06-29
JP2023527563A5 JP2023527563A5 (enExample) 2024-06-06
JP7843248B2 true JP7843248B2 (ja) 2026-04-09

Family

ID=78722933

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022573609A Active JP7843248B2 (ja) 2020-05-29 2021-05-28 ＡＰＲＩＬ結合抗体によるＩｇＡ腎症を治療する方法
JP2026056121A Pending JP2026126199A (ja) 2020-05-29 2026-03-30 ＡＰＲＩＬ結合抗体によるＩｇＡ腎症を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026056121A Pending JP2026126199A (ja) 2020-05-29 2026-03-30 ＡＰＲＩＬ結合抗体によるＩｇＡ腎症を治療する方法

Country Status (11)

Country Link
US (1) US20210379183A1 (enExample)
EP (1) EP4157339A4 (enExample)
JP (2) JP7843248B2 (enExample)
KR (1) KR20230017223A (enExample)
CN (1) CN115996748A (enExample)
AU (1) AU2021279035A1 (enExample)
BR (1) BR112022024262A2 (enExample)
CA (1) CA3179812A1 (enExample)
IL (1) IL298370A (enExample)
MX (1) MX2022014995A (enExample)
WO (1) WO2021243298A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
CN116322775A (zh) 2020-06-02 2023-06-23 阿雷斯贸易股份有限公司 IgA肾病治疗的相关方法
AU2023262513A1 (en) 2022-04-25 2024-12-05 Visterra, Inc. Antibody molecules to april and uses thereof
AU2023366516A1 (en) 2022-10-28 2025-05-15 Aduro Biotech Holdings, Europe B.V. Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody
WO2024099272A1 (zh) * 2022-11-07 2024-05-16 信瑞诺医药（上海）有限公司 用于治疗IgA肾病的内皮素受体拮抗剂和糖皮质激素的组合
WO2026050274A2 (en) * 2024-08-27 2026-03-05 Paragon Therapeutics, Inc. April binding proteins, compositions, and methods of use thereof
WO2026067804A1 (zh) * 2024-09-30 2026-04-02 信立泰(成都)生物技术有限公司 一种抗april抗体或其抗原结合片段及用途
WO2026122561A2 (en) 2024-12-03 2026-06-11 Otsuka America Pharmaceutical, Inc. Methods of treating sjögren's disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502918A (ja) 2015-01-09 2018-02-01 アデュロ バイオテック ホールディングス ヨーロッパ ベスローテン フエンノートシャップ 改変されたａｐｒｉｌ結合抗体

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74798C2 (uk) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
PT1610820E (pt) * 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
KR20080074120A (ko) * 2005-10-13 2008-08-12 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
CA2681728C (en) * 2007-03-27 2015-12-22 Zymogenetics, Inc. Combination of blys and/or april inhibition and immunnosuppressants for treatment of autoimmune disease
RU2481824C2 (ru) * 2008-10-29 2013-05-20 Аблинкс Н.В Препараты однодоменных антигенсвязывающих молекул
WO2010100056A2 (en) * 2009-03-02 2010-09-10 Stichting Top Institute Pharma Antibodies against a proliferating inducing ligand (april)
SG184355A1 (en) * 2010-03-01 2012-11-29 Progenics Pharm Inc Concentrated protein formulations and uses thereof
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
KR20180066241A (ko) * 2015-10-28 2018-06-18 아두로 바이오테크, 인코포레이티드 “인터페론 유전자의 자극제”-의존성 신호전달을 활성화시키기 위한 조성물 및 방법
JOP20170017B1 (ar) * 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
US12103979B2 (en) * 2017-04-28 2024-10-01 Amgen Inc. N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US11034768B2 (en) * 2017-10-30 2021-06-15 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
CN110464842B (zh) * 2018-05-11 2022-10-14 信达生物制药(苏州)有限公司 包含抗pcsk9抗体的制剂及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502918A (ja) 2015-01-09 2018-02-01 アデュロ バイオテック ホールディングス ヨーロッパ ベスローテン フエンノートシャップ 改変されたａｐｒｉｌ結合抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Eur. J. Pharm. Biopharm.，2011年，Vol. 78，pp. 208-212
J. Pharm. Sci.，2007年，Vol. 96, No. 1，pp. 1-26

Also Published As

Publication number Publication date
WO2021243298A1 (en) 2021-12-02
MX2022014995A (es) 2023-02-09
JP2023527563A (ja) 2023-06-29
EP4157339A1 (en) 2023-04-05
US20210379183A1 (en) 2021-12-09
CA3179812A1 (en) 2021-12-02
EP4157339A4 (en) 2024-08-07
JP2026126199A (ja) 2026-08-04
BR112022024262A2 (pt) 2023-02-23
IL298370A (en) 2023-01-01
AU2021279035A1 (en) 2023-02-02
KR20230017223A (ko) 2023-02-03
CN115996748A (zh) 2023-04-21

Similar Documents

Publication Publication Date Title
US20210379183A1 (en) METHODS OF TREATING IgA NEPHROPATHY WITH AN APRIL BINDING ANTIBODY
KR102576012B1 (ko) 고농도 항-c5 항체 제형
TWI802882B (zh) 包含抗IL-23p19抗體的製劑、其製備方法和用途
US20240002517A1 (en) Protein formulations and uses thereof
CN109661240B (zh) 抗体制剂
JP2024528724A (ja) 抗ｐｄ－１抗体医薬組成物及びその使用
CN110960490A (zh) 一种抗egfr抗体偶联药物组合物及其用途
AU2021311673A1 (en) PD-L1/LAG-3 bispecific antibody preparation, and preparation method therefor and use thereof
TW202128133A (zh) 重組全人源抗ｔｉｇｉｔ單株抗體製劑及其製備方法和用途
WO2020108621A1 (zh) 一种cd40抗体药物组合物及其用途
EP4146700A1 (en) Aqueous pharmaceutical composition of levilimab
WO2025218746A1 (en) Methods of treating rheumatoid arthritis
EP4685155A1 (en) Preparation containing anti-pd-1/mutant il-2 immunoconjugate
EP4501313A1 (en) Preparations containing anti-claudin18.2/cd3 bispecific antibody, preparation method therefor and use thereof
RU2787595C2 (ru) Высококонцентрированные составы антител к c5
RU2847524C2 (ru) Высококонцентрированные составы антител к c5
JP2025515325A (ja) 抗ｉｌｔ４抗体又はその抗原結合フラグメントの医薬製剤及び使用方法
WO2026092387A1 (zh) 包含抗igf-1r和抗cd40l抗体的药物组合及其用途和使用方法
HK40093161A (en) Pharmaceutical composition of anti-ctla-4 antibody and use thereof
CN116803420A (zh) 靶向PD-1和TGFβ的双功能蛋白药物组合物及其用途

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20240513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240513

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240528

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240528

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260330

R150 Certificate of patent or registration of utility model

Ref document number: 7843248

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150